Inflammasome Drug Discovery Services

Generate translational evidence with integrated neuroscience and immunology expertise

Explore topics

Why is an integrated approach essential for successful inflammasome drug discovery?

Inflammasomes sit at the intersection of innate immunity and neuroinflammation. Whether you're developing therapies for Alzheimer's disease, Parkinson's disease, multiple sclerosis, autoimmune diseases or systemic inflammatory disorders, selecting the appropriate biological models early is essential for demonstrating efficacy, selectivity and mechanism.

Developing therapies against NLRP3 and other inflammasome pathways demands more than a single screening assay. Success depends on selecting biologically relevant models, confirming mechanism of action, understanding downstream immune responses, and generating evidence that translates confidently into later development.

Concept Life Sciences combines neuroscience, immunology and translational biology expertise with advanced cellular models and orthogonal functional readouts to help reduce development risk and accelerate better decisions.

Speak to an Expert

‍‍

Download Inflammasome Whitepaper

Why inflammasome drug discovery remains challenging

Despite growing interest in inflammasome biology, many programs struggle because early experimental systems fail to predict clinical performance.

Teams commonly face:

Challenge	Impact
Poorly predictive screening models	Weak translation into human biology
Uncertain mechanism of action	Difficult candidate prioritization
Limited understanding of selectivity	Increased safety risk
Lack of integrated functional data	Higher program attrition
CNS inflammation complexity	Poor confidence in neurodegenerative indications
Choosing meaningful biomarkers	Difficult go/no-go decisions

Better models create better decisions, and our scientists help design studies that answer the questions most likely to de-risk your program and not simply generate more data. Read more about our neuroscience models.

Overcoming attrition in inflammasome therapeutics starts with smarter preclinical design. By integrating selectivity, efficacy, toxicity, and mechanism of action (MoA) studies earlier, we can improve success rates and accelerate development.

Read the full article in European Biopharmaceutical Review (EBR) Spring 2026. © Samedan Ltd

Human-relevant inflammasome models

Select the right biological model for every development stage

Robust, reliable assays are key to translating preclinical results into clinical success. We offer a suite of assays that probe the NLRP3 inflammasome which can be adapted to investigate other inflammasome targets:

Assay Model	Best Suited For
THP-1 macrophages	High-throughput screening to identify lead candidates and concentrations for testing in primary cell assays.
Primary human macrophages	Translational confirmation. Supports phenotype polarization (M1, M2, TAM-like) for disease relevance.
iPSC-derived microglia	Neuroinflammation and CNS programs. Enables genetic background modeling and disease mutation studies.
Organotypic brain slices	Test lead compounds in complex 3D ex vivo models to de-risk transition to in vivo studies.
Custom disease models	Novel mechanisms and emerging targets.

Supporting neuroscience and immunology programs

Inflammasome signaling contributes to numerous neurological and immune-mediated diseases. Our scientists combine expertise from neuroscience and immunology to design studies that reflect disease biology, whether your program focuses on:

Alzheimer's disease
Parkinson's disease
Multiple sclerosis
ALS
Autoimmune disease
Chronic inflammatory disorders
Rare inflammatory diseases
Fibrosis
Metabolic disease

Cross-disciplinary expertise enables studies that examine both immune activation and downstream tissue responses within a single experimental strategy.

Beyond individual assays: Integrated translational biology

Drug discovery programs rarely fail because one assay performs poorly. More often they fail because individual experiments do not collectively answer the biological questions needed to progress confidently.

Our scientists design integrated studies that combine:

The result is decision-ready evidence rather than disconnected datasets.

Ensure your drug discovery program is grounded in a strong scientific foundation to accelerate your path to the clinic. Download our whitepaper on Inflammasome Biology in Drug Discovery, watch our webinar or read the accompanying poster for deeper data insights.

Are you ready to advance your inflammasome therapeutics?

Speak to a specialist today

Inflammasome FAQs

Q: How do I choose the right inflammasome model?

A: The optimal model depends on your therapeutic target, development stage and indication. Early screening often benefits from robust immortalized cell systems, while primary human cells, iPSC-derived microglia and organotypic brain slices provide greater translational relevance for candidate validation.

Q: Do you only support NLRP3?

A: No. While NLRP3 is our most established platform, our assay development expertise can be adapted to investigate additional inflammasome pathways and emerging therapeutic targets.

Q: Can you support neuroinflammation programs?

A: Yes. We combine inflammasome biology with specialist neuroscience capabilities including human iPSC-derived microglia, astrocytes, neuronal models and organotypic brain slices to support neurodegenerative disease research.

Q: How do you assess mechanism of action?

A: We combine orthogonal functional endpoints including cytokine secretion, caspase-1 activation, ASC speck formation, pyroptosis, biomarker analysis and high-content imaging to confirm on-target activity and biological effects.

Q: Can studies be customized?

A: Yes. Every program is designed around your target biology, therapeutic hypothesis and development objectives, allowing scientists to combine assays, models and analytical technologies into a tailored experimental strategy.